Gossamer Bio, Inc.
GOSS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.29 | -0.26 | -0.22 | 0.01 |
| FCF Yield | -16.85% | -15.93% | -17.31% | -14.35% |
| EV / EBITDA | -12.91 | -12.62 | -11.44 | -14.18 |
| Quality | ||||
| ROIC | -20.50% | -15.78% | -12.41% | -10.85% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.75 | 1.23 | 1.08 | 1.07 |
| Growth | ||||
| Revenue 3-Year CAGR | 3,531,611.81% | 3,426,593.00% | 4,994,427.35% | 4,858,625.92% |
| Free Cash Flow Growth | -18.53% | -12.03% | -10.76% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -5.00 | -5.18 | -4.96 | -6.23 |
| Interest Coverage | -14.13 | -13.40 | -13.20 | -12.41 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 62.50 | 59.91 | 51.22 | 62.54 |